Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect

Current Drug Discovery Technologies

Volumn 6, Issue 1, 2009, Pages 43-51

  Sajja, Hari Krishna ^a   East, Michael P ^a   Mao, Hui ^a   Wang, Y Andrew ^b   Nie, Shuming ^a   Yang, Lily ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OCEAN NANOTECH LLC   (United States)

Author keywords

Drug delivery; Molecular diagnosis; Multifunctional nanoparticles; Nanomedicine; Nanotechnology; Nanotherapeutics; Targeted therapy; Tumor imaging

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARBON NANOTUBE; DENDRIMER; ERLOTINIB; GEFITINIB; LIPOSOME; NANOMATERIAL; NANOPARTICLE; POLYMER; SMALL INTERFERING RNA; TRASTUZUMAB;

DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG TARGETING; ENCAPSULATION; HUMAN; NANOMEDICINE; NANOTECHNOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 62149103699     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016309787581066     Document Type: Review

References (104)

1. Caruthers S.D., Wickline S.A., Lanza G.M.: Nanotechnological applications in medicine. Curr. Opin. Biotechnol. 18(1), 26-30, (2007).
2. Portney N.G., Ozkan M.: Nano-oncology: drug delivery, imaging, and sensing. Anal. Bioanal. Chem. 384(3), 620-630, (2006).
3. Alivisatos P.: The use of nanocrystals in biological detection. Nat. Biotechnol. 22(1), 47-52, (2004).
4. Sinha R., Kim G.J., Nie S., Shin D.M.: Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 5(8), 1909-1917, (2006).
5. Yezhelyev M.V., Gao X., Xing Y., Al-Hajj A., Nie S., O'Regan R.M.: Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol. 7(8), 657-667, (2006).
6. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., van de Kaa C.H., de la Rosette J., Weissleder R.: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348(25), 2491-2499, (2003).
7. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature. Science 296(5577), 2404-2407, (2002).
8. Cunin F., Schmedake T.A., Link J.R., Li Y.Y., Koh J., Bhatia S.N., Sailor M.J. Biomolecular screening with encoded porous-silicon photonic crystals. Nat. Mater. 1(1), 39-41, (2002).
9. Cao Y.C., Jin R., Mirkin C.A.: Nanoparticles with Raman spectroscopic fingerprints for DNA and RNA detection. Science 297(5586), 1536-1540, (2002).
10. http://www.abraxane.com/professional/efficacy.aspx
11. Stern S.T., McNeil S.E.: Nanotechnology Safety Concerns Revisited. Toxicol. Sci. 101(1), 4-21, (2008).
12. Kim K.Y.: Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine 3(2), 103-110, (2007).
13. Linkov F., Yurkovetsky Z., Lokshin A.: Biomarker approaches to the development of cancer screening tests: can cancer blood tests become a routine health check-up? Future Oncol. 3(3), 295-298, (2007).
14. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., et al.: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439), 531-537, (1999).
15. Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., et al.: Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24(3), 227-235, (2000).
16. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511, (2000).
17. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., et al.: Molecular portraits of human breast tumours. Nature 406(6797), 747-752, (2000).
18. Bittner M., Meltzer P., Chen Y., Jiang Y., Seftor E., Hendrix M., Radmacher M., Simon R., et al.: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795), 536-540, (2000).
19. Rubin M.A., Zerkowski M.P., Camp R.L., Kuefer R., Hofer M.D., Chinnaiyan A.M., Rimm D.L.: Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am. J. Pathol. 164(3), 831-840, (2004).
20. Taylor B.S., Varambally S., Chinnaiyan A.M.: Differential proteomic alterations between localised and metastatic prostate cancer. Br. J. Cancer 95(4), 425-430, (2006).
21. Varambally S., Yu J., Laxman B., Rhodes D.R., Mehra R., Tomlins S.A., Shah R.B., Chandran U., et al.: Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8(5), 393-406, (2005).
22. Maurya P., Meleady P., Dowling P., Clynes M.: Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res. 27(3A), 1247-1255, (2007).
23. Cho W.C. Contribution of oncoproteomics to cancer biomarker discovery. Mol. Cancer 6(4), 25, (2007).
24. Caron M., Choquet-Kastylevsky G., Joubert-Caron R.: Cancer immunomics using autoantibody signatures for biomarker discovery. Mol. Cell. Proteomics 6(7), 1115-1122, (2007).
25. Khalil A.A.: Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci. 98(2), 201-213, (2007).
26. Peng X.H., Cao Z.H., Xia J.T., Carlson G.W., Lewis M.M., Wood W.C., Yang L.: Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res. 65(5), 1909-1917, (2005).
27. Hinestrosa M.C., Dickersin K., Klein P., Mayer M., Noss K., Slamon D., Sledge G., Visco F.M.: Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat. Rev. Cancer 7(4), 309-315, (2007).
28. Levenson V.V.: Biomarkers for early detection of breast cancer: what, when, and where? Biochim. Biophys. Acta 1770(6), 847-856, (2007).
29. Hopkins T.G., Burns P.A., Routledge M.N.: DNA methylation of GSTP1 as biomarker in diagnosis of prostate cancer. Urology 69(1), 11-16, (2007).
30. Nelson W.G., De Marzo A.M., Isaacs W.B.: Prostate cancer. N. Engl. J. Med. 349(4), 366-381, (2003).
31. Nie S., Xing Y., Kim G.J., Simons J.W.: Nanotechnology applications in cancer. Annu. Rev. Biomed. Eng. 9, 257-288, (2007).
32. Wang M.D., Shin D.M., Simons J.W., Nie S.: Nanotechnology for targeted cancer therapy. Expert Rev. Anticancer Ther. 7(6), 833-837, (2007).
33. Chan W.C., Maxwell D.J., Gao X., Bailey R.E., Han M., Nie S.: Luminescent quantum dots for multiplexed biological detection and imaging. Curr. Opin. Biotechnol. 13(1), 40-46, (2002).
34. Kim S.W., Zimmer J.P., Ohnishi S., Tracy J.B., Frangioni J.V., Bawendi M.G.: Engineering InAs(x)P(1-x)/InP/ZnSe III-V alloyed core/shell quantum dots for the near-infrared. J. Am. Chem. Soc. 127(30), 10526-10532, (2005).
35. Alivisatos A.P., Gu W., Larabell C.: Quantum dots as cellular probes. Annu. Rev. Biomed. Eng. 7, 55-76, (2005).
36. Gao X., Yang L., Petros J.A., Marshall F.F., Simons J.W., Nie S.: In vivo molecular and cellular imaging with quantum dots. Curr. Opin. Biotechnol. 16(1), 63-72, (2005).
37. Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., Sundaresan G., Wu A.M., et al.: Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307(5709), 538-544, (2005).
38. Gao X., Cui Y., Levenson R.M., Chung L.W., Nie S.: In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22(8), 969-976, (2004).
39. Ballou B., Ernst L.A., Waggoner A.S.: Fluorescence imaging of tumors in vivo. Curr. Med. Chem. 12(7), 795-805, (2005).
40. Slotkin J.R., Cahill K.S., Tharin S.A., Shapiro E.M.: Cellular magnetic resonance imaging: nanometer and micrometer size particles for noninvasive cell localization. Neurotherapeutics 4(3), 428-433, (2007).
41. Rapalino O., Lazarov-Spiegler O., Agranov E., Velan G.J., Yoles E., Fraidakis M., Solomon A., Gepstein R., et al.: Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat. Med. 4(7), 814-821, (1998).
42. Weissleder R., Stark D.D., Engelstad B.L., Bacon B.R., Compton C.C., White D.L., Jacobs P., Lewis J.: Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am. J. Roentgenol. 152(1), 167-173, (1989).
43. Caruthers S.D., Winter P.M., Wickline S.A., Lanza G.M.: Targeted magnetic resonance imaging contrast agents. Methods Mol. Med. 124, 387-400, (2006).
44. Sundstrom J.B., Mao H., Santoianni R., Villinger F., Little D.M., Huynh T.T., Mayne A.E., Hao E., et al.: Magnetic resonance imaging of activated proliferating rhesus macaque T cells labeled with superparamagnetic monocrystalline iron oxide nanoparticles. J. Acquir. Immune Defic. Syndr. 35(1), 9-21, (2004).
45. Shapiro E.M., Sharer K., Skrtic S., Koretsky A.P.: In vivo detection of single cells by MRI. Magn. Reson. Med. 55(2), 242-249, (2006).
46. Lee J.H., Huh Y.M., Jun Y.W., Seo J.W., Jang J.T., Song H.T., Kim S., Cho E.J., et al.: Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat. Med. 13(1), 95-99, (2007).
47. Johannsen M., Gneveckow U., Taymoorian K., Thiesen B., Waldofner N., Scholz R., Jung K., Jordan A., et al.: Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int. J. Hyperthermia 23(3), 315-323, (2007).
48. Loo C., Lowery A., Halas N., West J., Drezek R.: Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 5(4), 709-711, (2005).
49. Konig K.: Multiphoton microscopy in life sciences. J. Microsc. 200(Pt 2), 83-104, (2000).
50. O'Neal D.P., Hirsch L.R., Halas N.J., Payne J.D., West J.L.: Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett. 209(2), 171-176, (2004).
51. Wong S.S., Joselevich E., Woolley A.T., Cheung C.L., Lieber C.M.: Covalently functionalized nanotubes as nanometre-sized probes in chemistry and biology. Nature 394(6688), 52-55, (1998).
52. Kam N.W., O'Connell M., Wisdom J.A., Dai H.: Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc. Natl. Acad. Sci. USA 102(33), 11600-11605, (2005).
53. Zhang Z., Yang X., Zhang Y., Zeng B., Wang S., Zhu T., Roden R.B., Chen Y., et al.: Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin. Cancer Res. 12(16), 4933-4939, (2006).
54. Liu Z., Cai W., He L., Nakayama N., Chen K., Sun X., Chen X., Dai H.: In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2(1), 47-52, (2007).
55. Wang D., Chen L.: Temperature and pH-responsive single-walled carbon nanotube dispersions. Nano Lett. 7(6), 1480-1484, (2007).
56. Simeonova P.P.: Evaluation of carbon nanotube toxicity. Nanomedicine 2(4), 304-305, (2006).
57. Sakthivel T., Florence A.T.: Dendrimers & Dendrons: Facets of pharmaceutical nanotechnology. Drug Deliv. Technol. 3(5), 50-60, (2003).
58. Majoros I.J., Myc A., Thomas T., Mehta C.B., Baker J.R., Jr.: PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 7(2), 572-579, (2006).
59. Kukowska-Latallo J.F., Candido K.A., Cao Z., Nigavekar S.S., Majoros I.J., Thomas T.P., Balogh L.P., Khan M.K., et al.: Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65(12), 5317-5324, (2005).
60. Krishna S.H., Srinivas N.D., Raghavarao K.S., Karanth N.G.: Reverse micellar extraction for downstream processing of proteins/enzymes. Adv. Biochem. Eng. Biotechnol. 75, 119-183, (2002).
61. Simoes S., Moreira J.N., Fonseca C., Duzgunes N., de Lima M.C.: On the formulation of pH-sensitive liposomes with long circulation times. Adv. Drug Deliv. Rev. 56(7), 947-965, (2004).
62. Needham D., Anyarambhatla G., Kong G., Dewhirst M.W.: A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 60(5), 1197-1201, (2000).
63. Wang S., Gao R., Zhou F., Selke, M.: Nanomaterials and single oxygen photosensitizers: Potential applications in photodynamic therapy. J. Mater. Chem. 14(4), 487-493, (2004)
64. Mukherjee P., Bhattacharya R., Mukhopadhyay D.: Gold nanoparticles bearing functional anti-cancer drug and anti-angiogenic agent: A "2 in 1" system with potential application in cancer therapeutics. J. Biomed. Nanotechnol. 1(2), 224-228, (2005).
65. Vijayaraghavalu S., Raghavan D., Labhasetwar V.: Nanoparticles for delivery of chemotherapeutic agents to tumors. Curr. Opin. Investig. Drugs 8(6), 477-484, (2007).
66. Goren D., Horowitz A.T., Zalipsky S., Woodle M.C., Yarden Y., Gabizon A.: Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer 74(11), 1749-1756, (1996).
67. Versluis A.J., Rump E.T., Rensen P.C., Van Berkel T.J., Bijsterbosch M.K.: Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy. Pharm. Res. 15(4), 531-537, (1998).
68. Lasic D.D., Vallner J.J., Working P.K.: Sterically stabilized liposomes in cancer therapy and gene delivery. Curr. Opin. Mol. Ther. 1(2), 177-185, (1999).
69. Slepushkin V.A., Salem II, Andreev S.M., Dazin P., Duzgunes N.: Targeting of liposomes to HIV-1-infected cells by peptides derived from the CD4 receptor. Biochem. Biophys. Res. Commun. 227(3), 827-833, (1996).
70. Rao M., Alving C.R.: Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. Adv. Drug Deliv. Rev. 41(2), 171-188, (2000).
71. Kobayashi H., Kawamoto S., Saga T., Sato N., Ishimori T., Konishi J., Ono K., Togashi K., et al.: Avidin-dendrimer-(1B4M-Gd)(254): a tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI. Bioconjug. Chem. 12(4), 587-593, (2001).
72. Quintana A., Raczka E., Piehler L., Lee I., Myc A., Majoros I., Patri A.K., Thomas T., et al.: Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 19(9), 1310-1316, (2002).
73. Chen C.Z., Cooper S.L.: Interactions between dendrimer biocides and bacterial membranes. Biomaterials 23(16), 3359-3368, (2002).
74. Boas U., Heegaard P.M.: Dendrimers in drug research. Chem. Soc. Rev. 33(1), 43-63, (2004).
75. Rojo J., Delgado R.: Glycodendritic structures: promising new antiviral drugs. J. Antimicrob. Chemother. 54(3), 579-581, (2004).
76. Witvrouw M., Fikkert V., Pluymers W., Matthews B., Mardel K., Schols D., Raff J., Debyser Z., et al.: Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Mol. Pharmacol. 58(5), 1100-1108, (2000).
77. Olivier J.C., Fenart L., Chauvet R., Pariat C., Cecchelli R., Couet W.: Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 16(12), 1836-1842, (1999).
78. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., Alyautdin R., von Briesen H., et al.: Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 20(3), 409-416, (2003).
79. Raghuvanshi R.J., Mistra A., Talwar G.P., Levy R.J., Labhasetwar V.: Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid. J. Microencapsul. 18(6), 723-732. (2001).
80. Watnasirichaikul S., Davies N.M., Rades T., Tucker I.G.: Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions. Pharm. Res. 17(6), 684-689, (2000).
81. Elbayoumi T.A., Pabba S., Roby A., Torchilin V.P.: Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J. Liposome Res. 17(1), 1-14, (2007).
82. Romberg B., Hennink W.E., Storm G.: Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 25(1), 55-71, (2008).
83. Torchilin, V.P.: Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58(14), 1532-1555, (2006).
84. Patri A.K., Myc A., Beals J., Thomas T.P., Bander N.H., Baker J.R., Jr.: Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug. Chem .15(6), 1174-1181, (2004).
85. Buck S.M., Koo Y.E., Park E., Xu H., Philbert M.A., Brasuel M.A., Kopelman R.: Optochemical nanosensor PEBBLEs: photonic explorers for bioanalysis with biologically localized embedding. Curr. Opin. Chem. Biol. 8(5), 540-546, (2004).
86. Duncan R.: Designing polymer conjugates as lysosomotropic nanomedicines. Biochem. Soc. Trans. 35(Pt 1), 56-60, (2007).
87. Padera T.P., Stoll B.R., Tooredman J.B., Capen D., di Tomaso E., Jain, R.K.: Pathology: cancer cells compress intratumour vessels. Nature 427(6976), 695, (2004).
88. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., McDonald D.M.: Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156(4), 1363-1380, (2000).
89. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K.: Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54(13), 3352-3356, (1994).
90. van Etten B., ten Hagen T.L., de Vries M.R., Ambagtsheer G., Huet T., Eggermont A.M.: Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras. Br. J. Cancer 86(3), 436-442, (2002).
91. McKee T.D., Grandi P., Mok W., Alexandrakis G., Insin N., Zimmer J.P., Bawendi M.G., Boucher Y., et al.: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66(5), 2509-2513, (2006).
92. Jain R.K.: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58-62, (2005).
93. Izumi Y., Xu L., di Tomaso E., Fukumura D., Jain R.K.: Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416(6878), 279-280, (2002).
94. Kozin S.V., Winkler F., Garkavtsev I., Hicklin D.J., Jain R.K., Boucher Y.: Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatmentnaive tumors. Cancer Res. 67(11), 5076-5082, (2007).
95. Harris T.J., von Maltzahn G., Derfus A.M., Ruoslahti E., Bhatia S.N.: Proteolytic actuation of nanoparticle self-assembly. Angew. Chem. Int. Ed. Engl. 45(19), 3161-3165, (2006).
96. Ntziachristos V., Bremer C., Weissleder R.: Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur. Radiol. 13(1), 195-208, (2003).
97. Kircher M.F., Weissleder R., Josephson L.: A dual fluorochrome probe for imaging proteases. Bioconjug. Chem. 15(2), 242-248, (2004).
98. Schellenberger E.A., Sosnovik D., Weissleder R., Josephson L.: Magneto/optical annexin V, a multimodal protein. Bioconjug. Chem. 15(5), 1062-1067, (2004).
99. 3 beads-CdSe/ZnS quantum dots core-shell nanocomposite particles for cell separation. Nano Lett. 4(3), 409-413, (2004).
100. Gu H., Zheng R., Zhang X., Xu B.: Facile one-pot synthesis of bifunctional heterodimers of nanoparticles: a conjugate of quantum dot and magnetic nanoparticles. J. Am. Chem. Soc. 126(18), 5664-5665, (2004).
101. Mulder W.J., Koole R., Brandwijk R.J., Storm G., Chin P.T., Strijkers G.J., de Mello Donega C., Nicolay K., et al.: Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett. 6(1), 1-16, (2006).
102. van Tilborg G.A., Mulder W.J., Chin P.T., Storm G., Reutelingsperger C.P., Nicolay K., Strijkers G.J.: Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug. Chem. 17(4), 865-868, (2006).
103. Yang L., Mao H., Cao Z., Wang A.Y., Peng X., Wang X., Karna P., Adams A., et al.: Development of peptide-conjugated superparamagnetic iron oxide (IO) nanoparticles for in vivo imaging and therapy of pancreatic cancer. Proceedings of NSTI Nanotechnology Conference, Vol. 2, 17-20, (2006).
104. Bhatt R.S., Seth P., Sukhatme V.P.: Biomarkers for monitoring antiangiogenic therapy. Clin. Cancer Res. 13(2 Pt 2), 777s-780s, (2007).